Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
For now, however, its still premature to administer prophylactic GLP-1 RAs to patients being treated with lithium. If the GLP-1 RAs can indeed be shown to be nephroprotective, it would affect the risk-benefit evaluation, where currently, many patients dont want to take lithium and many prescribers dont want to prescribe it, so many people who could potentially benefit could now consider it as a viable treatment option, Dr McIntyre said
Healthcare providers should discuss this likelihood during shared decision-making conversations, along with considerations of cost, insurance coverage, medication availability, and perioperative management (as these agents delay gastric emptying)
"For example, deciding not to weigh oneself, or not to talk about dieting, weight loss, et cetera when you're sitting around talking to your colleagues
Anxiety about whether the new medication will work, frustration during retitration periods when appetite returns, and the cognitive load of tracking two different dosing protocols all take a psychological toll
Support from the European the Union Seventh Framework Programme (FP7/2007-2013) under grant agreement number 279153 (Beta-JUDO), the Regional Research Council in Uppsala-rebro, Sweden, the Swedish Diabetes Foundation, the Swedish Society for Diabetology, the Gillbergska Foundation, Swedish Research Council (2016-01040), and AstraZeneca was received for the study
Zepbound (tirzepatide) Approved uses: People with overweight or obesity and moderate-to-severe obstructive sleep apnea Drug type: Once-weekly injection Doses: 2.5 mg (initial dose), 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg Cost: With commercial insurance that includes Zepbound coverage, the cost of a three-month prescription is as low as $25
